`
`
`
`
` abcbdefgehihbh
` !"#$%&'(!)#01$ 2345675889
`p qpra sp a
`@A$$
`rq p q t
`#&B&$#&'0CD($ED1$#&B&$#&'0CD($
`#&'FG$HI'C $&PI'FC&#D$ED1$
`#&B&$#&'0CD($)D$G&!0C#QD$C# A1$
`#&B&$#&'0CD($)D$ &HHI' C!$
`G&!0C#QD$C# A1$#&B&$#&'0CD($C# A1$
`#&B&$#&'0CD($'IDI' G$ I#FI'$
`DIFF!I1$C# A1$#&B&$#&'0CD($
`PG'H I)FC !$C#0)DF'CID$!P1$RST$
`I!C$!C!!"$#0$ &HP#"1$$UV8V6W467XY`
` u
`r rv u r rv
`v ibwxywy
`r v
`IA$PR$DSS SS$!$%R$#A$$
`0RSR$ $DSRS$!$%R$#A$$
`de$PfTR$D1$D$gee$
`#h$&RS1$!$de$
`Fi$ge$gj$
`TRSRASRSkRRhAlm$
`RASS SSkRRhAlm$
`vv vw y
`!S$GA$%hS$nop`q4r`s5rV`nV6W56tu`
`g$@S$v$w$mlR1$dw$x$
`#h$"y1$#"$eeeje$
`FwSi$$gjz$
`SA hSkATRAlm$$
`
`
`
`Case 2:23-cv-01020-JDC-KK Document 54 Filed 11/03/23 Page 2 of 3 PageID #: 312
`Case 2:23-cv-01020-JDC-KK Document 54 Filed 11/03/23 Page 2 of 3 PagelD #: 312
`
` !"#$
`% &'' " !"#$%
` !"#$% ( ")& $
`!"#$% 0) '"1 "!1 $20
`
`Attorneys for Defendants Nordisk US Holdings Inc.,
`Novo Nordisk US Commercial Holdings Inc., Novo
`Nordisk Inc., Novo Nordisk Research Center Seattle,
`Inc., and Novo Nordisk Pharmaceutical Industries, LP
`
`
`
`Case 2:23-cv-01020-JDC-KK Document 54 Filed 11/03/23 Page 3 of 3 PageID #: 313
`
` ! "# $%% "
`! "# ! "# & "'$ #! "#
`('%" )"! ) 0( 1 ")2)3%'4 %' 56%
`$%1 78$5 9@A'1 B)" 1)) 5 &) $(" ) CD73@7E@
`' )% )2 ' ""%1 2 4 % )%0A
` F %3 G#DHDG
`& 1 ")2)3% #
`IPIQRSTUTQVWXYQ`abcbYUTUdQQ
`8( 3 706e CfgDh@
` $ )1 706e GGGhh@
`ipiqrsitpsuvvrvswwxs
`yHC(2
`) g9HH
`
` A #06yHCGh
` F79Hg@9fCGDGg
` )1 A"%
`1 3 A"%
`QIPIQWbYUQ QbWUQQ
`0 eA 7cbWQTQSYQcYUSUQ
`pwisxxvuswwxsrs
`CD9C6 ) ' 6% "
`Dy'5
`
` A# CHHDHCCHg
` 1' F7DCD@GG9gfgE
` 3A )11 "%
`dddWbUYePQfWbQRYfYUTUdPQgWbSPhQi`Q WXSUPQ
`jUkQgWWQgWbSPhQi`QVWllYbSTXQ WXSUPQ
`jUkQgWWQgWbSPhQjUkQgWWQgWbSPhQmYPYTbQ
`VYUdYbQ`YTddXYkQjUkQTUQgWWQgWbSPhQ
`nTblTYadSTXQjUaPdbSYPkQn
`
`